Press Releases Quest PharmaTech Inc.

Equities

QPT

CA74836M1068

Market Closed - Toronto S.E. Other stock markets 01:25:29 2024-05-03 pm EDT			5-day change	1st Jan Change
0.02 ^CAD	-33.33%		0.00%	-63.64%

Jan. 30	Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	MT
Jan. 30	Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quest Receives Cash Dividend Payment from OncoQuest	Jan. 30	AQ
Quest PharmaTech Inc. - Oregovomab Phase III Clinical Study fails futility analysis, Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits	Jan. 24	AQ
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits	Jan. 23	AQ
Quest PharmaTech Provides Corporate Update	23-09-13	AQ
Quest PharmaTech Announces Results from AGM	23-07-14	AQ
Quest PharmaTech Provides Product Development Update	23-07-10	AQ
Quest PharmaTech Provides Corporate Update	23-06-09	AQ
Canadian Investment Regulatory Organization Trade Resumption - QPT	23-06-07	AQ
Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc.	23-06-06	AQ
Canadian Investment Regulatory Organization Trading Halt - QPT	23-06-06	AQ
Quest PharmaTech Provides Corporate Update	23-06-02	AQ
Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License	22-09-28	AQ
Quest PharmaTech Announces Results from AGM	22-07-21	AQ
Quest PharmaTech Provides Corporate Update	22-04-19	AQ
Quest PharmaTech : September 1, 2021 OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer	21-09-02	PU
Quest PharmaTech : OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer	21-09-01	AQ
Quest PharmaTech : July 7, 2021 Quest PharmaTech Announces Results from AGM	21-07-08	PU
Quest PharmaTech : Announces Results from AGM	21-07-07	AQ
Quest PharmaTech : June 1, 2021 Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists	21-06-01	PU
Quest PharmaTech : announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists	21-06-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Quest PharmaTech Inc.

Equities

QPT

CA74836M1068

Press Releases

Filters